FDA-cleared profile

Annalise Enterprise CTB Triage-OH

Annalise-AI Pty Ltd · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Aid triage and prioritization of adult patients aged 22 years or older with non-contrast brain CT studies containing features suggestive of obstructive hydrocephalus by providing study-level output to an order and imaging management system; the notification is not for standalone clinical decision-making or to rule out the finding.

Clinical role
Post-acquisition case-level triage and notification that prioritizes suspected obstructive-hydrocephalus studies in an image and order management worklist without lowering an existing study priority.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Limited by the FDA indication to non-contrast brain CT and patients aged 22 years or older. Results are not standalone clinical decisions, do not rule out obstructive hydrocephalus, and do not replace clinical assessment. Performance evidence used independent adult cohorts from five U.S. hospital-network sites and should not be generalized beyond the studied inputs and operating points.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Aid triage and prioritization of adult patients aged 22 years or older with non-contrast brain CT studies containing features suggestive of obstructive hydrocephalus by providing study-level output to an order and imaging management system; the notification is not for standalone clinical decision-making or to rule out the finding.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM-compliant non-contrast brain CT studies from the intended adult population; the FDA performance cohorts included slice-thickness groups of 1.5 mm or less and greater than 1.5 mm through 5.0 mm.
  • Who uses it?Intended users: Trained clinicians who, within their scope of practice, are qualified to interpret brain CT studies.
  • What does the software produce?Output: Study-level notification to an image and order management system for suspected obstructive hydrocephalus and worklist prioritization; the device does not direct attention to a specific image portion.
  • What is its most important limitation?Key limitation: Limited by the FDA indication to non-contrast brain CT and patients aged 22 years or older. Results are not standalone clinical decisions, do not rule out obstructive hydrocephalus, and do not replace clinical assessment. Performance evidence used independent adult cohorts from five U.S. hospital-network sites and should not be generalized beyond the studied inputs and operating points.

Clinical takeaway. Clinical role: Aid triage and prioritization of adult patients aged 22 years or older with non-contrast brain CT studies containing features suggestive of obstructive hydrocephalus by providing study-level output to an order and imaging management system; the notification is not for standalone clinical decision-making or to rule out the finding.

Evidence takeaway. Evidence from the reviewed source record: Standalone performance used an independent retrospective anonymized dataset of 175 cases for slice thickness ≤1.5 mm (75 positive, 100 negative) and 191 cases for >1.5 mm to ≤5.0 mm (84 positive, 107 negative) collected from five U.S. hospital-network sites, including community hospitals and academic medical centers. Ground truth used two ABR-certified protocol-trained neuroradiologists with a third in disagreement. FDA sensitivity and specificity were reported separately by slice-thickness range and operating point for obstructive hydrocephalus. A separate internal bench triage-effectiveness study of 277 positive cases reported turnaround of 81.6 seconds (95% CI 80.3-82.9), a latency endpoint distinct from diagnostic performance.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Aid triage and prioritization of adult patients aged 22 years or older with non-contrast brain CT studies containing features suggestive of obstructive hydrocephalus by providing study-level output to an order and imaging management system; the notification is not for standalone clinical decision-making or to rule out the finding.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Post-acquisition case-level triage and notification that prioritizes suspected obstructive-hydrocephalus studies in an image and order management worklist without lowering an existing study priority.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM-compliant non-contrast brain CT studies from the intended adult population; the FDA performance cohorts included slice-thickness groups of 1.5 mm or less and greater than 1.5 mm through 5.0 mm.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Study-level notification to an image and order management system for suspected obstructive hydrocephalus and worklist prioritization; the device does not direct attention to a specific image portion.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Medical care environment with workflow performed in parallel to standard clinical interpretation; the FDA packet does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Trained clinicians who, within their scope of practice, are qualified to interpret brain CT studies.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Limited by the FDA indication to non-contrast brain CT and patients aged 22 years or older. Results are not standalone clinical decisions, do not rule out obstructive hydrocephalus, and do not replace clinical assessment. Performance evidence used independent adult cohorts from five U.S. hospital-network sites and should not be generalized beyond the studied inputs and operating points.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
Standalone performance used an independent retrospective anonymized dataset of 175 cases for slice thickness ≤1.5 mm (75 positive, 100 negative) and 191 cases for >1.5 mm to ≤5.0 mm (84 positive, 107 negative) collected from five U.S. hospital-network sites, including community hospitals and academic medical centers. Ground truth used two ABR-certified protocol-trained neuroradiologists with a third in disagreement. FDA sensitivity and specificity were reported separately by slice-thickness range and operating point for obstructive hydrocephalus. A separate internal bench triage-effectiveness study of 277 positive cases reported turnaround of 81.6 seconds (95% CI 80.3-82.9), a latency endpoint distinct from diagnostic performance.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone performance used an independent retrospective anonymized dataset of 175 cases for slice thickness ≤1.5 mm (75 positive, 100 negative) and 191 cases for >1.5 mm to ≤5.0 mm (84 positive, 107 negative) collected from five U.S. hospital-network sites, including community hospitals and academic medical centers. Ground truth used two ABR-certified protocol-trained neuroradiologists with a third in disagreement. FDA sensitivity and specificity were reported separately by slice-thickness range and operating point for obstructive hydrocephalus. A separate internal bench triage-effectiveness study of 277 positive cases reported turnaround of 81.6 seconds (95% CI 80.3-82.9), a latency endpoint distinct from diagnostic performance.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Obstructive-hydrocephalus standalone sensitivity: slice thickness ≤1.5 mm, operating points 0.149943: 97.3% (95% CI 93.3%-100.0%), 0.185900: 94.7% (89.3%-98.7%), and 0.281473: 92.0% (85.3%-97.3%); >1.5 mm and ≤5.0 mm, operating points 0.100591: 97.6% (94.0%-100.0%), 0.149943: 95.2% (90.5%-98.8%), 0.185900: 94.0% (89.3%-98.8%), and 0.281473: 88.1% (81.0%-94.0%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The FDA endpoint is case-level standalone sensitivity for obstructive hydrocephalus and varies by slice-thickness range and operating point.

Reported specificity
Obstructive-hydrocephalus standalone specificity: slice thickness ≤1.5 mm, operating points 0.149943: 94.0% (95% CI 89.0%-98.0%), 0.185900: 95.0% (90.0%-99.0%), and 0.281473: 97.0% (93.0%-100.0%); >1.5 mm and ≤5.0 mm, operating points 0.100591, 0.149943, 0.185900, and 0.281473: 95.3% (90.7%-99.1%) at each listed operating point.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The FDA endpoint is case-level standalone specificity for obstructive hydrocephalus and is bounded by the studied slice-thickness ranges and operating points.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Harrison.ai Comprehensive Care (CTB - obstructive hydrocephalus) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested version3.3+
  • Samplen=366
  • Sites5
  • IndependenceIndependence not established

K231094

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231094. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant non-contrast brain CT studies from the intended adult population; the FDA performance cohorts included slice-thickness groups of 1.5 mm or less and greater than 1.5 mm through 5.0 mm.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K231094: Annalise Enterprise CTB Triage-OH

  2. Routing

    Source context, not route validation: The FDA packet states that the device interfaces with image and order management systems such as PACS/RIS to obtain CT studies and return a prioritization notification; exact current interface versions and local compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K231094: Annalise Enterprise CTB Triage-OH

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Study-level notification to an image and order management system for suspected obstructive hydrocephalus and worklist prioritization; the device does not direct attention to a specific image portion.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K231094: Annalise Enterprise CTB Triage-OH

  5. Viewer/worklist/report

    Unresolved route: Study-level notification to an image and order management system for suspected obstructive hydrocephalus and worklist prioritization; the device does not direct attention to a specific image portion.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K231094: Annalise Enterprise CTB Triage-OH

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA packet states that the device interfaces with image and order management systems such as PACS/RIS to obtain CT studies and return a prioritization notification; exact current interface versions and local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Harrison.ai's Data Privacy FAQs (issued 2025-09-25) state a compliance baseline aligned with the GDPR and the Australian Privacy Act; that medical image data processed by its solutions is encrypted and pseudonymised or de-identified with measures to minimise re-identification risk; that customer patient images are not collected to train AI models; and that technical, organisational and administrative safeguards protect personal data. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the FDA applicant is Annalise-AI Pty Ltd; Harrison.ai's own Annalise Enterprise page (2023-08-09, harrison.ai/annalise-enterprise/) states Annalise.ai is now Harrison-AI Medical Pty Ltd, an entity the Harrison.ai privacy notice lists in Section 14, and annalise.ai/privacy-policy redirects to that notice. The FAQ names Harrison.ai. Company-level statement; exact-release scope is not established.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Annalise Enterprise CTB Triage-OH; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231094
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-08-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K231094 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K231094: Annalise Enterprise CTB Triage-OH

    U.S. Food and Drug Administration - Published 2023-08-15 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Harrison.ai Comprehensive Care (CTB - obstructive hydrocephalus) model card (K231094)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231094

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Harrison.ai: Data Privacy FAQs

    Harrison.ai - Published 2025-09-25 - Accessed 2026-10-26

    Scope: security

Research history

  1. K231094 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253818

Annalise Enterprise

Harrison-AI Medical Pty, Ltd.

Authorized purpose: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-03-03
FDA-cleared K251195

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-01-27
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history